Skip to content.

Medicenna Therapeutics Corp. raises US$20M

Date Closed

August 11, 2022

Lead Office

Québec City


20.00 Million USD

On August 11, 2022, Medicenna Therapeutics Corp. ("Medicenna") closed its previously announced marketed underwritten public offering of units in Canada and in the United States for an aggregate gross proceeds of approximately US$20 million. Medicenna plans to use the net proceeds of the offering primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines.

McCarthy Tétrault advised Medicenna with a team led by Charles-Antoine Soulière that included Vincent Laurin, Mireille Trottier, Annie Poirier-Simard (Securities), Marie-Soleil Landry, and Geneviève Favreau (Tax).